Clinical Trials Browser

Phase 2 × Hyperuricemia × rasburicase × Clear all

Leukemia, Lymphoma, Myelodysplastic Syndromes, Tumor Lysis Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hyperuricemia

NCT00664144 2012-03-07

GRAAL2

Phase 2 Terminated

33 enrolled

Hyperuricemia

NCT00631579 2009-10-02

Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma

Phase 2 Completed

50 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Hyperuricemia

NCT00290992 2009-03-30

Rasburicase for Hyperuricemia

Phase 2 Completed

30 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Nutritional and Metabolic Diseases, Hyperuricemia

Clinical Trials

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

GRAAL2

Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma

Rasburicase for Hyperuricemia